



Addendum: Statement on nutritional supplements and piracetam for children with Down syndrome

Manisha Balwani, MD for the American College of Medical Genetics and Genomics (ACMG) Professional Practice and Guidelines Committee

Genetics in Medicine (2020) 22:2127; <https://doi.org/10.1038/s41436-020-0847-9>

The original statement was published in the ACMG newsletter in 1996.

This document was retired by the ACMG Board of Directors as of 27 April 2020 with the following addendum:

Based on the current literature,^{1,2} the use of piracetam or other nutritional supplements in the health supervision for children with Down syndrome is not recommended.

REFERENCES

1. Lobaugh NJ, Karaskov V, Rombaugh V, et al. Piracetam therapy does not enhance cognitive functioning in children with Down syndrome. *Arch Pediatr Adolesc Med.* 2001;155:442–448.
2. Bull MJ, Committee on Genetics. Health supervision for children with Down syndrome. *Pediatrics.* 2011;128:393–406. Reaffirmed in *Pediatrics.* 2018;141:e20180518.

Correspondence: ACMG (documents@acmg.net)

Submitted 14 May 2020; accepted: 14 May 2020
Published online: 8 June 2020